Concomitant Administration of Interleukin-2 During Therapeutic Vaccinations Against Cancer: The Good, the Bad, or the Evil?
- 1 August 2005
- journal article
- other
- Published by American Society of Clinical Oncology (ASCO) in Journal of Clinical Oncology
- Vol. 23 (22) , 5265-5267
- https://doi.org/10.1200/jco.2004.00.9837
Abstract
No abstract availableThis publication has 8 references indexed in Scilit:
- Immunologic and Clinical Outcomes of Vaccination With a Multiepitope Melanoma Peptide Vaccine Plus Low-Dose Interleukin-2 Administered Either Concurrently or on a Delayed ScheduleJournal of Clinical Oncology, 2004
- Lack of toxicity of therapy-induced T cell responses against the universal tumour antigen survivinVaccine, 2004
- Chemokines: multiple levels of leukocyte migration control☆Trends in Immunology, 2004
- Dynamic changes of specific T cell responses to melanoma correlate with IL-2 administrationSeminars in Cancer Biology, 2003
- Immunologic Monitoring of Cancer Vaccine Therapy: Results of a Workshop Sponsored by the Society for Biological TherapyJournal of Immunotherapy, 2002
- Identification of TRP-2 as a Human Tumor Antigen Recognized by Cytotoxic T LymphocytesThe Journal of Experimental Medicine, 1996
- Identification of the immunodominant peptides of the MART-1 human melanoma antigen recognized by the majority of HLA-A2-restricted tumor infiltrating lymphocytes.The Journal of Experimental Medicine, 1994
- Melanocyte lineage-specific antigen gp100 is recognized by melanoma-derived tumor-infiltrating lymphocytes.The Journal of Experimental Medicine, 1994